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Background: Lung cancer is still the leading cause of cancer-related mortality worldwide. Around 80 to 85% of
lung cancers are non-small cell lung cancer (NSCLC). Regional lymphatic metastasis is a frequent occurrence in
NSCLC, and the extent of lymphatic dissemination significantly determines the prognosis of patients with NSCLC.
Hence, identification of alternative treatments for these patients should be considered a priority. Liposomal
paclitaxel is a new formulation composed of paclitaxel and liposomes, with favorable pharmacokinetic properties. In
particular, it produces dramatically higher drug concentrations in the lymph nodes than occurs with the current
formulations of paclitaxel, thus we believe that patients with NSCLC with regional lymphatic metastasis may benefit
from this new drug. Cisplatin-based doublet chemotherapy is recommended as the first-line treatment for patients
with advanced NSCLC. We have designed a trial to assess whether first-line chemotherapy using liposomal
paclitaxel combined with cisplatin (LP regimen) is superior to gemcitabine combined with cisplatin (GP regimen) in
efficacy (both short-term and long-term efficacy) and safety (adverse events; AEs).
Method/Design: This is a prospective, open-label, controlled randomized clinical trial (RCT) to assess the
therapeutic effects and safety of liposomal paclitaxel. The study aims to enroll 126 patients, who will be randomly
allocated to one of the two treatment groups (LP and GP), with 63 patients in each group. Patients will receive four
to six cycles of the assigned chemotherapy, and primary outcome will be assessed every two cycles. Patients will be
recommended for surgery if the tumor becomes resectable. All participants will be followed up for at least
12 months. The objective response rate (ORR), changes in regional lymphatic metastasis (including number and
size) and TNM (tumor, node, metastasis) staging will be the primary outcome measures. Progression-free survival,
objective survival, median survival time, 1-year survival rate, toxicity, and time to disease progression will be the
secondary outcome measures.
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Conclusions: A systematic search has indicated that this proposed study will be the first RCT to evaluate whether
liposomal paclitaxel plus cisplatin will have beneficial effects, compared with gemcitabine plus cisplatin, on
enhancing ORR, changing TNM staging, improving long-term survival, and reducing the frequency of AEs for
patients with NSCLC with regional lymphatic metastasis.
Trial registration: www.chictr.org Identifier: ChiCTR-TRC-12602105
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Regional lymphatic metastasis was generally involved in
patients with NSCLC
Lung cancer has become the leading cause worldwide of
cancer-related mortality in both men and women [1].
Around 80 to 85% of lung cancers are non-small cell
lung cancer (NSCLC), adequate therapeutic planning is
largely dependent upon early diagnosis, and surgery is
still the preferred treatment for early-stage tumors [2].
However, it is known that approximately 70% of patients
with NSCLC have advanced local invasion and/or distant
metastasis at the time of diagnosis, and thus surgery is
not possible for these patients. Presence of regional
lymphatic metastasis is generally found in NSCLC even
in the early stages of tumor growth, partly because of
the wide distribution of lymphoid tissue in the lung, and
also because the extent of lymphatic dissemination also
significantly determines the clinical prognosis for
patients with NSCLC [3]. Therefore, therapeutic strat-
egies focusing on the issue of regional lymphatic metas-
tasis are of great importance not only for the control of
distant lung-cancer metastases, but also for reducing the
TNM (tumor, node, metastasis) stage and thus regaining
the opportunity for surgery.
Currently, cisplatin-based doublet chemotherapy con-
sisting of cisplatin combined with third-generation drugs
(paclitaxel, gemcitabine, vinorelbine, or docetaxel) is
commonly recommended as the standard treatment for
patients with advanced NSCLC [4-7]. However, the
pharmaceutical properties of the drugs or formulations,
including poor drug permeability through cell mem-
branes or tissue barriers, short circulating half-life, and
rapid metabolism, heavily influence the effectiveness of
tumor therapy [8]. Consequently, use of chemotherapy
drugs targeting regional lymph nodes remains to be fur-
ther explored and evaluated.
The specific pharmaceutical properties of liposomal
paclitaxel
Paclitaxel is a complex diterpenoid natural product, which
has become a first-line treatment for NSCLC. However,
because of its poor water solubility, paclitaxel has been
used in an encapsulated form with the organic co-solvents
ethanol and polyethoxylated castor oil (a formulationmarketed as TaxolW; Bristol-Myers Squibb, New York, NY,
USA) for clinical trials, but has been shown to cause toxic
effects, including life-threatening anaphylaxis [9]. Li-
posomal paclitaxel (Lipusu; Luye Pharma Group Ltd.,
Nanjing, China) is a new formulation of paclitaxel and
phosphatidylcholine liposomes. Pharmacokinetic studies
in animal models [10-12] have shown that, compared with
the current paclitaxel formulation, liposomal paclitaxel
has a significantly prolonged elimination half-life and
mean retention time, and an apparent larger volume of
distribution. Even more unexpected and exciting is that
the concentration of liposomal paclitaxel in tissues is dra-
matically higher than that of paclitaxel, especially in the
reticuloendothelial system, including the lymph nodes,
liver, and spleen. Several clinical studies [12-17] recently
indicated that the efficacy of liposomal paclitaxel equaled
or slightly exceeded that of the current paclitaxel (TaxolW)
formulation, while having a superior safety profile.
Hypothesis and study basis
We searched MEDLINE (from 1968 to 2012), EMBASE
(from 1977 to 2012), and the Cochrane Library (from
1953 to 2012), using selected key words including
‘liposomal paclitaxel (or paclitaxel liposomes)’, ‘lung can-
cer (or NSCLC)’, ‘lymphatic metastasis’ and ‘controlled
trial (or RCT)’. We did not find any clinical randomized
controlled trial (RCT) to date that had examined the
role of liposomal paclitaxel in patients with NSCLC with
regional lymphatic metastasis. The RCTs performed thus
far have focused on patients with advanced NSCLC as a
whole. In view of the pharmacokinetic characteristics of
liposomal paclitaxel in lymph nodes, we speculate that
this new formulation may represent a novel chemother-
apy drug, and could play a unique role in the treatment
of NSCLC with regional lymphatic metastasis. In this
paper, we outline our proposed protocol for a prospect-
ive open-label RCT aimed at testing this hypothesis.
Objective
This clinical trial aims to determine whether first-line
therapy using liposomal paclitaxel combined with cisplatin
(LP regimen) is more effective and safer than gemcitabine
combined with cisplatin (GP regimen) for patients with










Outcome assessment (Every 2 cycles)
Follow-up (Every 4 months) at least 12 months
If the tumor becomes resectable, surgery will be
recommended, and chemotherapy will go on after surgery
End of treatment (4~6 cycles in total)
/beginning of follow-up
Data analysis/End of the trial
Figure 1 Study flow chart.
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Study design
This clinical trial is a prospective open-label RCT. The
design of the study integrates rigorous, contemporary
clinical research methods in accordance with principles
set out in the Declaration of Helsinki and the Guidelines
for Good Clinical Practice. Reporting will be guided by
the most recent CONSORT statement [18]. The trial will
be comprised of three phases as follows.
 Phase 1 (recruitment and assignment of patients).
Consenting eligible participants will be recruited in
accordance with the inclusion/exclusion criteria and
assigned randomly to one of the two treatment
groups.
 Phase 2 (chemotherapy). Patients will receive four to
six cycles of chemotherapy with either LP or GP.
Adverse events (AEs) will be rigorously monitored
and recorded on a case report form (CRF).
 Phase 3 (follow-up). Patients will be followed up for
at least 12 months.
Ethics issue
The study has been approved by the ethics committee of
The First Affiliated Hospital of Third Military Medical
University (No: KY201006), and is registered at ChiCTR
(Chinese Clinical Trial Registry, trial Identifier ChiCTR-
TRC-12602105). All study participants will provide writ-
ten informed consent before participation.
Subjects
The study aims to enroll 126 patients with NSCLC who
meet both the inclusion and exclusion criteria below.
Using a random-number table (Center of Evidence-
Based Medicine and Clinical Epidemiology, The Second
Affiliated Hospital, Chongqing), patients will be ran-




 Hospitalized patients, both male and female, aged 18
to 75 years.
 Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2.
 Pathological diagnosis of non-small cell lung cancer,
TNM stage III to IV.
 Patients have never received any other
chemotherapy.
 In accordance with Response Evaluation Criteria in
Solid Tumors (RECIST) (RECIST)/WHO evaluation
criteria [19], at least one lesion, measurable or
evaluable, should be detected by chest CT, andregional lymph-node metastasis should also be
measurable or evaluable (including neck and
supraclavicular lymph-node metastasis).
 Expected survival ≥ 3 months.
 Hematology, liver and kidney function are normal,
the blood and biochemical indicators should meet
the following criteria:
 Bone marrow: absolute neutrophil count
(ANC) ≥ 1.5 × 109/l (1500/mm3)
 White blood cell count (WBCC) ≥ 4000 / mm3
 Platelet count ≥ 100,000 / mm3
 Hemoglobin ≥ 9 g/dl
 Liver: serum bilirubin ≤ 2 times the upper limit of
normal (ULN), aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) ≤ 2.5 times
ULN (or ≤ 5 times normal limit for ALT and AST
if liver metastasis present)
 Kidney: serum creatinine ≤ 1.5 times ULN.
 Good understanding and compliance by patients
with the pilot program, and provision of informed
consent.
Exclusion criteria
 Allergy to drugs.
 Pregnancy or lactation.
 History of cardiovascular disease (CVD), including
congestive heart failure (higher than New York
Heart Association level II).
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or new onset of angina (in the previous 3 months) or
myocardial infarction (in the previous 6 months).
 Presence of severe organic disease, including active
infection or CVD.
 Poor hepatic function or severe cirrhosis.
 Abnormal blood coagulation indicators.
 Poor condition or cachexia.
 Receipt of radiotherapy or other local physical
therapy within the previous 6 months.
 Receipt of other anti-cancer treatment (such as
chemotherapy, radiotherapy, immunosuppressive
agents, chemoembolization, or targeted agents).
 Recent (1 day to 4 weeks) participation in another
clinical drug trial.
 Other exclusion criteria: presence of other factors
that might lead to failure to participate in or
complete the clinical study (such as mental illness or
drug abuse), or might affect the analysis of results.
Study duration
Ongoing recruitment will continue for a maximum of
12 months (between June 2012 and June 2013) or until
126 individuals have been randomly assigned. The full
study is expected to be finished before December 2014,
when all the patients will have been followed up for at
least 12 months.
Examinations
Baseline examinations before treatment
 Medical history and demographic information,
including sex, age, address, and telephone details.
 Physical examination: height, weight, body surface
area, and vital signs, including heart rate, blood
pressure, respiration rate, and temperature.
 Physical status.
 Laboratory examinations: routine blood and urine
tests, liver and renal function.
 Electrocardiography (ECG) and chest computed
tomography (CT) scans.
The above examinations should be performed at least
1 week before chemotherapy begins. Tumors should be
evaluated on the basis of the tumor-associated symptoms,
physical examination of the superficial lesions, and results
of imaging studies.
Examinations during treatment
 Physical status, physical examination, routine blood
and urine tests, liver and renal function tests, and
ECG should be performed 2 to 3 days before each
chemotherapy cycle. Routine blood tests will be performed on days 4, 8,
and 14 after each cycle of chemotherapy. The times
will be increased if myelosuppression happens.
During the treatment, tumor will be evaluated 1 week
after every two cycles of chemotherapy, as described above.
Post-treatment examination
After treatment, participants will be required to return
to our department for follow-up every 4 months, at
which time repeat chest CT will be performed. Patients
will be informed that they should contact us immedi-
ately if AEs occur, and in such cases, any relevant
examinations needed for treatment will be undertaken.
Medical interventions
Based on the manufacturer’s instructions for use of
liposomal paclitaxel, pretreatment with intravenous
dexamethasone (5 to 10 mg), intravenous cimetidine
(300 mg) and intramuscular diphenhydramine (50 mg)
should be performed 30 minutes before chemotherapy.
The chemotherapy protocol is shown in Table 1.
The chemotherapy will be given as four to six cycles in
total, with every 21 days making up one cycle. One week
after every two cycles, the efficacy should be evaluated
in accordance with the RECIST criteria [19]. The chemo-
therapy should go on as long as the efficacy evaluation
indicates complete response (CR), partial response (PR),
or stable disease. Surgery will be suggested if the TNM
stage of the tumor reduces sufficiently for the lesion to
become resectable; in such cases, the relevant chemo-
therapy regimen will continue after surgery.
Assuming that there is a normal proportion of
granulocytes, the chemotherapy will be allowed to con-
tinue if the WBCC is within the range of 3.0 to 4.0 ×
109/l. If the WBCC falls within the range of 2.0 to 3.0 ×
109/l, chemotherapy will be stopped until the WBCC
increases to 3.0 × 109/l, or above. Granulocyte colony-
stimulating factor will be used for supportive treatment
if WBCC decreases to 2.0 × 109/l or below.
The doses of chemotherapy drugs will be decreased by
25% in the next cycle if IV degree toxicity (including
fever-induced neutropenia syndrome) emerges. Chemo-
therapy will be stopped in advance in cases of disease
progression, or unacceptable AEs,,even the patient may
not finish the chemotherapy plan.
Primary and secondary outcome measures
Primary
 Objective response rate (ORR): total of CR + PR.
 Change in regional lymphatic metastasis (including
number and size).
 Change in TNM staging.
Table 1 Chemotherapy procedure of both groups
Group Day Intervention Dosage Route of administration
Treatment (LP) 1 Liposomal paclitaxel 135 to 175 mg/m2 in saline (500 ml)1 IV drip (over 3 hours)
Cisplatin 75 mg/m2 in saline (500 ml)2 IV drip
Control (GP) 1 and 8 Gemcitabine 1000 mg/m2 in saline (100 ml) IV drip (over 30 min)
1 Cisplatin 75 mg/m2in saline (500 ml)2 IV drip
Abbreviations: GP, gemcitabine plus cisplatin; IV, intravenous; LP, liposomal paclitaxel.
1In the LP group, the liposomal paclitaxel must be used before cisplatin to avoid myelosuppression.
2At least 1500 ml of saline should be used for hydration before cisplatin infusion occurs.
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CT performed 4 weeks after each evaluation to confirm
if the result is CR or PR.Secondary
 Progression-free survival.
 Objective survival.
 Median survival time.
 Survival rate at 1 year.
 Time to disease progression.
 Toxicity.
Follow-up will consist of a telephone survey and a visit
to the clinic for re-examination. Chest CT will be
performed every 4 months. All patients will be followed
up for at least 12 months.Reporting of adverse events
Participants will be requested to report any AEs occur-
ring at any point throughout the whole trial, and the
doctors will give appropriate advice. All AEs will be
recorded in detail by the researchers, using a question-
naire that includes the following.
 Description of the AE and associated symptoms.
 When did the AE happen?
 What was the severity of the AE?
 How long did the AE last?
 What steps did the doctor or patient take after the
AE?
 What was the outcome of the AE?
The severity of the AE will be graded using National
Cancer Institute Common Toxicity Criteria (NCICTC,3rd
edition) for drug-associated AEs. Any AEs not included in
the classification will be evaluated using a four-grade scale:
I (mild), 2 (moderate), 3 (severe), and 4 (extremely severe,
i.e. life-threatening).
Severe AEs will be reported to the local authorities
within 24 hours, in accordance with the relevant
procedures.Sample size
The patient sample size is based on our preliminary
study, in which the ORRs of the LP and GP groups were
found to be about 65% and 35%, respectively. Using a
two-tailed significance level of 5% (α = 0.05) and power
of 90% (β = 0.10), we calculated the sample size
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where pt is the objective response rate of the LP group
(65%), pc is the objective response rate of the GP group
(35%), and p is the average response rate of both groups:
(65% + 35%)/2 = 50%. The sample size is then calculated
as: n1 = n2 ≈ 57.
Allowing a 10% drop-out rate during the study, we have
estimated that 63 patients will need to be enrolled in each
group, that is, 126 patients in total. Intention-to-treat
(ITT) analysis will be applied to minimize bias due to
drop-outs.Randomization method
Participants who satisfy the inclusion/exclusion criteria
will be randomized in a 1:1 ratio using a computer-
generated randomization number table at an independent
department (Center of Evidence-Based Medicine and Clin-
ical Epidemiology) who will not take part in the following
enrollment. To guarantee correct randomization, the
patient identification number and treatment allocation will
be provided by a central telephone-based randomization
system. After the patient's eligibility for enrollment has
been assessed, a unique randomization number will be
sent to our department through this central randomization
system, and the patient will be assigned to the appropriate
treatment group, thus each group will be allocated 63
participants. To minimize the possibility of bias in
reporting and assessing the endpoints, the trial will use a
PROBE (Prospective Randomized Open trial with Blinded
Evaluation of outcomes) design.
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Codes will be used to guarantee the privacy of the
participants. The CRF will be used to record data for all
participants. Basic patient information, results of all
examinations, chemotherapy programs used, AEs ob-
served, and follow-up results will be recorded in a timely
and truthful manner. These data will be held by both
our department and the sponsor, and cannot be
modified.
All participants will be enrolled in the final analysis re-
gardless of whether they withdraw at any point. A de-
scriptive statistical analysis will be performed for most of
the study variables. The mean, median, standard devi-
ation, maximum, and minimum will be calculated for
quantitative variables, and the absolute and relative
frequency, ratio, and CI calculated for qualitative and
ranked variables.
The statistical analysis will be carried out by a bio-
statistician at the Center of Evidence-Based Medicine
and Clinical Epidemiology, and the data will be
analyzed statistically using SPSS software (version
15.0; SPSS Inc., Chicago, IL, USA). The ITT popula-
tion, which will include all randomized patients, will
be used for efficacy analysis. In addition, a per-
protocol analysis will be performed on the efficacy
endpoint. The ORRs, 1-year survival rate, and toxicity
will be compared for the two groups using Fisher’s
exact test, and the survival curve will be analyzed
using the Kaplan-Meier method and log-rank test. A
two-tailed test will be used for all statistics. P < 0.05
will be considered significant, and 95% confidence
intervals will be calculated.
Discussion
Lung cancer is the most common cancer worldwide,
with NSCLC accounting for 85% of cases [20]. Over the
past 20 years, the 5-year survival rate for lung cancer
has remained low (about 15%) [21]. Over half of patients
with NSCLC present with regional lymphatic and/or dis-
tant metastasis (stage IIIB and IV) at time of diagnosis,
highlighting the need for new strategies to improve the
prognosis of this disease [7].
Liposomal paclitaxel is a new formulation composed
of paclitaxel packaged with liposomes, which has fa-
vorable pharmacokinetic properties including signifi-
cant prolongation of elimination half-life and mean
retention time, and an apparently larger volume of
distribution in vivo. In particular, the dramatically
higher drug concentration in the lymph nodes
compared with the current paclitaxel formulations
indicates that patients with NSCLC with regional
lymphatic metastasis may benefit from this new drug.
Because doublet chemotherapy composed of cisplatin
and gemcitabine has commonly been recommendedas first-line therapy for patients with advanced
NSCLC [4,22,23], we have designed this open-label
RCT to assess whether liposomal paclitaxel plus cis-
platin (LP) is superior to gemcitabine plus cisplatin
(GP) in efficacy (both short-term and long-term effi-
cacy) and safety (toxicity).
This study will be the first RCT to investigate whether
first-line therapy with liposomal paclitaxel can improve
the prognosis of patients with NSCLC with regional
lymphatic metastasis. The results of this study may pro-
vide a new chemotherapy regimen for clinicians and
promote new trials to focus on patients with NSCLC
with regional lymphatic metastasis.
Trial status
Currently, 57 patients have been enrolled and randomized
for this trial, and recruitment is ongoing.
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